Freenome (FRNM): Analyst Targets Point to +70% Upside

Key Takeaways

• The central target of $18 is the arithmetic mean of four verified analyst price targets, spanning a range of $17 to $21.
• With the stock near $10.57, reaching $18 implies a required upside of roughly 70%, a very large move for a recently listed company.
• The target is modestly above the stock's 52-week high of $17.50, set in September 2026, meaning the shares have already traded close to it once.
• Bullish support comes from coverage initiations at Guggenheim, TD Cowen, Jefferies, and BTIG, all of which rate the shares a Buy.
• The biggest risks are a heavily loss-making financial profile, a limited cash runway relative to spending, and binary FDA and commercialization milestones.
• Readers can find more on Major News, Today's Price Move, Forecast, and Earnings on dedicated pages.
• Explore Trending AI Robots to see AI-driven tools that monitor stocks and ETFs for changing signals.

Analyst Price Targets and Consensus View

Freenome, Inc. (FRNM) is a development-stage cancer diagnostics company that listed on the Nasdaq in July 2026 through a business combination. Four credible analyst price targets were reviewed, all issued in mid-August 2026 as coverage initiations. Guggenheim set a Buy with a $21 target, while TD Cowen, Jefferies, and BTIG each initiated at Buy with a $17 target. The arithmetic mean of these four targets is $18.00, which is used as the central target here. The low-to-high range is $17 to $21, a comparatively tight spread that signals broad agreement on valuation.

The reasoning behind the targets centers on Freenome's liquid-biopsy technology and its pipeline. TD Cowen highlights "differentiated" chemistry and partnerships with Abbott and Roche, projecting a sales ramp from roughly $107 million in 2026 toward $1 billion by 2035. BTIG's Mark Massaro describes the company as a pioneer in blood-based testing positioned across lung, colon, and multi-cancer screening, while Jefferies' Tycho Peterson points to reimbursement expansion as a key catalyst. Guggenheim frames the shares as a "compelling" risk/reward given a menu of assays and published research. No firm carries a Hold or Sell rating. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Current Market Position and Path Toward the Target

The latest verified price for FRNM is about $10.57, within a 52-week range of $9.71 to $17.50. Reaching $18 would require a gain of roughly 70%, which is a very large move. Notably, the shares spiked to $17.50 in late September 2026 before retreating roughly 40%, so the $18 target sits only slightly above a level the market has already tested. A move back toward the target would likely depend on clinical and regulatory progress rather than general market momentum, given the company's pre-revenue scale and dependence on catalysts such as the FDA review of its SimpleScreen CRC colorectal cancer test and the rollout of SimpleScreen Lung.

What Could Support a Move Toward the Target

• FDA and commercialization milestones: The SimpleScreen CRC test is under U.S. Food and Drug Administration review, and Freenome launched SimpleScreen Lung in October 2026, expanding its addressable market.
• Analyst backing: Four recent Buy initiations and a consensus "Strong Buy" stance reflect optimism about the liquid-biopsy opportunity and reimbursement expansion.
• Strategic partnerships: Relationships with Abbott and Roche, plus milestone and royalty payments from Exact Sciences, are cited by analysts as value drivers.
• Large addressable market: Blood-based multi-cancer early detection is viewed as a high-growth segment within diagnostics.

What Could Prevent the Target From Being Reached

• Heavy losses and cash burn: Trailing-twelve-month revenue was roughly $35 million against a net loss near $235 million, with cash of about $102 million and total debt near $311 million.
• Binary regulatory risk: A delay or setback in FDA approval or reimbursement decisions could materially reset expectations.
• Commercial execution: The path from approval to meaningful revenue and insurer coverage remains unproven.
• Valuation and volatility: The shares have shown wide swings since listing, and a sharp fall from the September high underscores sensitivity to news flow.

Technical Levels and Market Structure

The most relevant technical reference points are the 52-week high of $17.50 and the 52-week low of $9.71. The $17.50 level acts as a meaningful resistance zone, since the stock failed to hold above it in September and has since traded lower. A sustained move toward the $18 target would require clearing that prior high, while the $9.71 low marks the nearest durable support area below the current price. The recent decline from the September peak places the stock well below both its 50-day and 200-day moving averages, reflecting weakened near-term trend structure. From what I see, the pattern here aligns with what Tickeron’s AI Pattern Search Engine often flags in similar development-stage names.

Time Horizon and What Investors Should Monitor

Analyst price targets generally reflect a research horizon of roughly 12 months, and the four targets here were issued in August 2026 with no stated deviation from that convention. Investors should watch FDA decisions on SimpleScreen CRC, updates on reimbursement coverage from commercial insurers and the U.S. Preventive Services Task Force, quarterly cash position and spending, and any new partnership or royalty announcements. Revisions to analyst targets following earnings or clinical data will also matter, as will broader biotech sector sentiment.

Using AI Daily Buy/Sell Signals for Ongoing Monitoring

In my research process, Tickeron's AI Daily Buy/Sell Signals help track evolving conditions across thousands of stocks and ETFs. The system generates Buy, Sell, or Hold signals based on market shifts, technical factors, and AI analysis, which can surface potential turning points in volatile names like FRNM more efficiently than manual review alone.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Contributor

Sergey Savastiouk|Expert

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.

Notable companies

Industry description

Market Cap

High and low price notable news

Volume